Natera

Natera, Inc. announced the publication of over 300 peer-reviewed papers featuring its cell-free DNA testing technology. These publications, appearing in prominent journals, highlight breakthroughs in early disease detection and clinical decision-making across oncology, women’s health, and organ health. Key areas include Signatera’s utility in cancer management, advancements in non-invasive prenatal testing, and improved outcomes in transplant medicine. This milestone underscores Natera’s commitment to scientific validation and enhancing clinical care.